0001567619-22-000622.txt : 20220105
0001567619-22-000622.hdr.sgml : 20220105
20220105171639
ACCESSION NUMBER: 0001567619-22-000622
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220105
DATE AS OF CHANGE: 20220105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McAnear Justin J.
CENTRAL INDEX KEY: 0001786386
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39035
FILM NUMBER: 22512293
MAIL ADDRESS:
STREET 1: 10X GENOMICS, INC.
STREET 2: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 10x Genomics, Inc.
CENTRAL INDEX KEY: 0001770787
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 455614458
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 401-7300
MAIL ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: 10X Genomics, Inc.
DATE OF NAME CHANGE: 20190315
4
1
doc1.xml
FORM 4
X0306
4
2022-01-03
0
0001770787
10x Genomics, Inc.
TXG
0001786386
McAnear Justin J.
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
PLEASANTON
CA
94588
0
1
0
0
Chief Financial Officer
Class A Common Stock
2022-01-03
4
M
0
10000
5.04
A
48819
D
Class A Common Stock
2022-01-03
4
S
0
3583
145.1619
D
45236
D
Class A Common Stock
2022-01-03
4
S
0
4083
145.9556
D
41153
D
Class A Common Stock
2022-01-03
4
S
0
1334
146.9178
D
39819
D
Class A Common Stock
2022-01-03
4
S
0
500
148.0440
D
39319
D
Class A Common Stock
2022-01-03
4
S
0
500
149.1780
D
38819
D
Stock Option (right to buy)
5.04
2022-01-03
4
M
0
10000
0.00
D
2028-11-02
Class A Common Stock
10000
350159
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $144.54 to $145.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $145.54 to $146.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $146.54 to $147.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $147.58 to $148.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $148.66 to $149.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This option, originally for 600,000 shares, of which 249,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Eric S. Whitaker, as Attorney-in-Fact
2022-01-05